🔬 Optimize Your Drug Development with Pharmidex’s Expert Drug Metabolism Services!
August 14, 2024
Pharmidex offers comprehensive drug metabolism solutions using advanced UHPLC–high resolution mass spectrometry.
Our expert team specializes in identifying metabolically labile sites, cross-species metabolite profiling and structural characterization of metabolites.
We also address challenges like high clearance and reactive metabolism liabilities, helping you streamline your drug development process.
📈 Partner with us to enhance your drug's success and safety.
Discover More:
https://www.pharmidex.com/Drug-Metabolism-Service
#DrugMetabolism #Pharmidex #PharmaResearch #UHPLC #MassSpectrometry #DrugDevelopment #PharmaInnovation
We’re Hiring! Senior/Principal Scientist–In Vivo Pharmacologist
We’re delighted to welcome Gabrielle Georgiou and Dr. Mohammed Ahmad from the University of Hertfordshire as they begin their first experience in a scientific CRO environment here at Pharmidex ! This partnership is an exciting step in fostering early-career scientific talent by offering hands-on exposure to real-world drug discovery and preclinical research. A big thank you to the University of Hertfordshire for partnering with us to support the next generation of innovators. We’re proud to play a role in shaping future leaders in science through meaningful, practical learning opportunities. 👩🔬 👨🔬 Welcome to the team, Gabrielle and Mohammed!
At Pharmidex , we offer Brief Access Taste Aversion (BATA) testing, which is a behavioural assay that quantifies how test subjects respond to different compounds or formulations by measuring lick response and aversion. This helps identify: ✅ Bitter-tasting APIs ✅ Unpalatable excipients ✅ The success of taste-masking strategies ✅ Formulation-dependent compliance risks Get in touch if you’re developing oral formulations, paediatric drugs, or repurposing bitter APIs, this could be the data your IND package needs.
